{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(11)"],"submitter":["Chang Q"],"pubmed_abstract":["<h4>Background</h4>For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed to investigate the effect and safety of neoadjuvant immunotherapy for patients with resectable NSCLC including those with coexisting COPD and the effect on patients' lung function.<h4>Methods</h4>Data of patients with resectable NSCLC who received neoadjuvant immunotherapy at the Shanghai Chest Hospital were retrospectively analyzed.<h4>Results</h4>A total of 57 patients were enrolled and 18 of those were with coexisting COPD. For COPD patients, the objective response rate (ORR), major pathological response (MPR), and pathological complete response (pCR) were 44.4%, 55"],"journal":["Journal of thoracic disease"],"pagination":["7546-7560"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11635264"],"repository":["biostudies-literature"],"pubmed_title":["Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease."],"pmcid":["PMC11635264"],"pubmed_authors":["Qian J","Li J","Chang Q","Zhu Y","Lu H","Chu T","Wang S","Qiang H","Shen Y"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.","description":"<h4>Background</h4>For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed to investigate the effect and safety of neoadjuvant immunotherapy for patients with resectable NSCLC including those with coexisting COPD and the effect on patients' lung function.<h4>Methods</h4>Data of patients with resectable NSCLC who received neoadjuvant immunotherapy at the Shanghai Chest Hospital were retrospectively analyzed.<h4>Results</h4>A total of 57 patients were enrolled and 18 of those were with coexisting COPD. For COPD patients, the objective response rate (ORR), major pathological response (MPR), and pathological complete response (pCR) were 44.4%, 55","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-03T23:26:38.462Z","creation":"2025-04-03T23:26:38.462Z"},"accession":"S-EPMC11635264","cross_references":{"pubmed":["39678908"],"doi":["10.21037/jtd-24-811"]}}